(株)免疫生物研究所の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2013/08/30 | 日証協 | 23,290株 | -0.17% | 110株 | -97.44% | 17,794株 | +0.19% | 251株 | -84.92% |
2013/08/23 | 日証協 | 23,330株 | +2.64% | 4,300株 | +372.53% | 17,761株 | +1.91% | 1,665株 | +927.78% |
2013/08/16 | 日証協 | 22,730株 | -12.14% | 910株 | -51.08% | 17,428株 | -13.87% | 162株 | -74% |
2013/08/09 | 日証協 | 25,870株 | -6.59% | 1,860株 | -52.26% | 20,235株 | -3.03% | 623株 | -62.49% |
2013/08/02 | 日証協 | 27,694株 | +8.71% | 3,896株 | +42.66% | 20,867株 | +9.33% | 1,661株 | -31.65% |
2013/07/26 | 日証協 | 25,474株 | +5.9% | 2,731株 | -55.45% | 19,086株 | +5.71% | 2,430株 | +157.96% |
2013/07/19 | 日証協 | 24,054株 | -0.73% | 6,130株 | +2965% | 18,055株 | -0.19% | 942株 | -24.22% |
2013/07/12 | 日証協 | 24,230株 | -14.2% | 200株 | -83.19% | 18,090株 | -9.9% | 1,243株 | +21.86% |
2013/07/05 | 日証協 | 28,240株 | -16.1% | 1,190株 | +230.56% | 20,077株 | -20.89% | 1,020株 | +126.67% |
2013/06/28 | 日証協 | 33,660株 | -19.03% | 360株 | -96.17% | 25,377株 | -19.99% | 450株 | -95.82% |
2013/06/21 | 日証協 | 41,570株 | +16.12% | 9,400株 | -22.89% | 31,717株 | +30.01% | 10,760株 | -12.21% |
2013/06/14 | 日証協 | 35,800株 | +45.06% | 12,190株 | +62.97% | 24,396株 | +32.78% | 12,256株 | +376.89% |
2013/06/07 | 日証協 | 24,680株 | -8.66% | 7,480株 | -1.97% | 18,373株 | -7.05% | 2,570株 | +26.23% |
2013/05/31 | 日証協 | 27,020株 | +22.32% | 7,630株 | -57.59% | 19,767株 | +14.81% | 2,036株 | -78.95% |
2013/05/24 | 日証協 | 22,090株 | +17.88% | 17,990株 | +268.65% | 17,217株 | -2.54% | 9,670株 | +185.17% |
2013/05/17 | 日証協 | 18,740株 | -2.85% | 4,880株 | -37.6% | 17,666株 | +20.29% | 3,391株 | -52.17% |
2013/05/10 | 日証協 | 19,290株 | +13.2% | 7,820株 | +113.66% | 14,686株 | +5.91% | 7,090株 | +1717.95% |
2013/05/02 | 日証協 | 17,040株 | -15.05% | 3,660株 | +838.46% | 13,866株 | -16.19% | 390株 | -84.95% |
2013/04/26 | 日証協 | 20,060株 | -7.81% | 390株 | -90.8% | 16,544株 | -5.27% | 2,592株 | -33.02% |
※株式分割は考慮していませんのでご注意ください。